Resources from the same session
507O - EXCLAIM-2: Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)+ locally advanced/metastatic NSCLC
Presenter: Pasi Jänne
Session: Presidential Symposium
Resources:
Abstract
Slides
Webcast
Invited Discussant 507O
Presenter: Ross Soo
Session: Presidential Symposium
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Presidential Symposium
Resources:
Webcast
LBA1 - Efficacy and safety of adjuvant alectinib vs platinum-based chemotherapy (CT) in patients (pts) from Asia with resected, early-stage ALK+ non-small cell lung cancer (NSCLC): A sub analysis of ALINA
Presenter: Jin Seok Ahn
Session: Presidential Symposium
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Presidential Symposium
Resources:
Webcast
208O - Asian subgroup analysis of the THOR phase III study: Erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer and selected fibroblast growth factor receptor alterations
Presenter: Nobuaki Matsubara
Session: Presidential Symposium
Resources:
Abstract
Slides
Webcast
Invited Discussant 208O
Presenter: Enrique Grande
Session: Presidential Symposium
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Presidential Symposium
Resources:
Webcast